Problems in hemophilia therapy.
At present, the future of patients with hemophilia A may be regarded with more optimism due to advances in diagnosis and management which have occurred in recent years. However, a number of problems are still unresolved and others are now emerging against this optimistic background. The development of an inhibitor specifically destroying factor VIII coagulant activity renders the management at best difficult. It has been recognized recently that multitransfused hemophiliacs have a high incidence of abnormal liver function tests, and there is preliminary evidence that these are the expression of chronic active liver disease. This review is focused on these pitfalls of hemophilia care and emphasizes the recent developments in these fields and their impact on the pattern of life of hemophiliacs.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005169:Factor VIII / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D008107:Liver Diseases / Q000209:etiology; D012709:Serum Albumin / Q000627:therapeutic use; D065227:Transfusion Reaction
D012709:Serum Albumin; D005169:Factor VIII